Information on the relationship between the plasma concentration of nonsteroidal anti-inflammatory drugs (NSAIDs) and clinical response in rheumatoid arthritis is sparse. As a result treatment is often relatively empirical. Standard doses are prescribed and an apparent lack of response leads either to the prescription of another drug, or an increase in the dose beyond that recommended. This study investigated 18 patients given three doses (500, 1000 and 1500 mg/day) of naproxen in a randomized double-blind design for 12 days at a time. Using a linear modelling approach we found that three out of four clinical response measurements improved linearly with increasing naproxen trough concentrations, suggesting that most patients will achieve an...
Contains fulltext : mmubn000001_045933413.pdf (publisher's version ) (Open Access)...
Naprosyn CR 500 mg, a new controlled-release (CR) tablet formulation of naproxen, is suggested for u...
We have studied the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurren...
Ninety patients with active rheumatoid arthritis took part in a cross-over trial comparing diclofena...
rheumatoid arthritis. Extended trial. 121 patients with active rheumatoid arthritis, 91 of whom had ...
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) which preferentially inhibits cycloo...
Indoprofen, despite its relatively short plasma half-life, was just as effective given twice daily a...
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to control pain in rheumatoid arthriti...
Background: Therapeutic Drug Monitoring is part of standard patient care and utilizes pharmacokineti...
Objectives: Inadequate response to adalimumab can be caused by insufficient blockade of the target t...
Contains fulltext : 88603.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
Objective To determine a concentration-effect curve of adalimumab in rheumatoid arthritis (RA) patie...
Aims To investigate the concentration-effect relationship and pharmacokinetics of leflunomide in pat...
Clinical response in patients with rheumatoid arthritis (RA) treated with biologic agents can be inf...
Response to drug therapy in rheumatoid arthritis (RA) is often inconsistent and frequently disappoin...
Contains fulltext : mmubn000001_045933413.pdf (publisher's version ) (Open Access)...
Naprosyn CR 500 mg, a new controlled-release (CR) tablet formulation of naproxen, is suggested for u...
We have studied the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurren...
Ninety patients with active rheumatoid arthritis took part in a cross-over trial comparing diclofena...
rheumatoid arthritis. Extended trial. 121 patients with active rheumatoid arthritis, 91 of whom had ...
Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) which preferentially inhibits cycloo...
Indoprofen, despite its relatively short plasma half-life, was just as effective given twice daily a...
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to control pain in rheumatoid arthriti...
Background: Therapeutic Drug Monitoring is part of standard patient care and utilizes pharmacokineti...
Objectives: Inadequate response to adalimumab can be caused by insufficient blockade of the target t...
Contains fulltext : 88603.pdf (publisher's version ) (Closed access)OBJECTIVE: To ...
Objective To determine a concentration-effect curve of adalimumab in rheumatoid arthritis (RA) patie...
Aims To investigate the concentration-effect relationship and pharmacokinetics of leflunomide in pat...
Clinical response in patients with rheumatoid arthritis (RA) treated with biologic agents can be inf...
Response to drug therapy in rheumatoid arthritis (RA) is often inconsistent and frequently disappoin...
Contains fulltext : mmubn000001_045933413.pdf (publisher's version ) (Open Access)...
Naprosyn CR 500 mg, a new controlled-release (CR) tablet formulation of naproxen, is suggested for u...
We have studied the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurren...